Paietta, Elisabeth;
Li, Xiaochun;
Richards, Sue;
Racevskis, Janis;
Dewald, Gordon W.;
Rowe, Jacob M.;
Tallman, Martin S;
Lazarus, Hillard M;
Litzow, Mark R.;
Goldstone, Anthony H.;
Wiernik, Peter
Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se
You can manage bookmarks using lists, please log in to your user account for this.
Media type:
E-Article
Title:
Outcome in Philadelphia Chromosome Positive (Ph+) Adult ALL Patients (Pts) May Be More Determined by CD25 Expression Than by Ph Status Per Se
Contributor:
Paietta, Elisabeth;
Li, Xiaochun;
Richards, Sue;
Racevskis, Janis;
Dewald, Gordon W.;
Rowe, Jacob M.;
Tallman, Martin S;
Lazarus, Hillard M;
Litzow, Mark R.;
Goldstone, Anthony H.;
Wiernik, Peter
Description:
<jats:title>Abstract</jats:title>
<jats:p>On intergroup phase III trial, MRC UKALLXII/ECOG2993, 25% of 613 ECOG patients were positive for Ph or its molecular equivalent, BCR/ABL; all were B-lineage ALLs (B-ALL). When compared to Ph(−) B-ALL, Ph(+) ALL had more blasts expressing CD25 (α-chain of interleukin-2 [IL-2] receptor) (p=3E-31), CD34 (p=4E-10), CD13 (p=3.9E-16) and CD33 (p=3.5E-09), and blasts with higher density of CD10 (p=9.6E-12). There was no difference in antigen expression profiles between pts with e1a2 (N=107) and b2a2/b3a2 (N=48) BCR/ABL transcripts. Complete remission (CR) rate was lower (p= 7.4E-6) and overall survival (OS) was shorter in Ph(+) compared with Ph(−) B-ALL (p=6.5E-5). There was no difference in outcome between e1a2 and b2a2/b3a2 pts (p=0.65). CD25 was the most powerful prognostic indicator in Ph(+) cases, both for CR (p=0.004) and OS (p=1.3E-05). Strikingly, CD25 negatively affected OS in a continuous fashion; 1% increase in CD25 was related to a 1% increase in the hazard of death. On the other hand, CD25 expression was not associated with OS in Ph(−) pts (p=0.66). Among 152 Ph(+) pts, 30 lacked CD25 expression, 24 with e1a2 and 6 with b2a2/b3a2 transcripts. When analyzed separately, CD25(−)Ph(+) pts had outcome indistinguishable from that of Ph(−) pts (p=0.89). Compared to CD25(+)Ph(+) pts, CD25(−) Ph(+) pts had lower WBC counts at presentation (p=4.1E-05). Both CD25(+) and CD25(−) Ph(+) blasts expressed the γ-chain but not the β-chain of the IL-2 receptor, arguing against the presence of a functional IL-2 receptor. There was no association between CD25 expression or outcome and the presence of additional cytogenetic abnormalities seen in 52% of Ph(+) pts. To further examine the prognostic impact of CD25, BCR/ABL levels were quantitated by real-time PCR in 136 Ph(+) pts at presentation. There was no correlation between presenting BCR/ABL levels and blast count (p=0.98), achievement of CR (p=0.73), or OS (p=0.67). However, higher blast counts at diagnosis were associated with shorter survival (p=0.003). BCR/ABL levels were measured in 43 pts 1 month after induction therapy. Changes in BCR/ABL after therapy were classified as undetectable, &gt;90% reduction, &gt;50% reduction, or no change. While CR status did not correlate with BCR/ABL reduction (p=0.97), the chance of survival ranked in the order of undetectable (p=0.01), &gt;90% reduction (p=0.05), &gt;50% reduction (p=0.37), or no change (p=0.87). CD25 expression at presentation correlated with that order (p=0.002). CD25(−)Ph(+) pts fell into the group with undetectable BCR/ABL levels after treatment, whereas pts with highest initial CD25 expression fell into the group with no change. In conclusion, CD25(−)Ph(+) blasts are more sensitive to non-TKI therapy than CD25(+) Ph(+) blasts. Outcome in Ph(+) ALL is thus determined by CD25 expression rather than the presence of Ph per se.</jats:p>
<jats:p>RESPONSE CD25(+)Ph(+) CD25(−)Ph(+) Ph(−) B-Lin ALL n 122 30 308 % CR Rate 57% 71% 81% MedianOS (months) 12.2 30.2 27.7</jats:p>